TRAIL signaling is often impaired in cancer cells, and this hurdle to TRAIL tumor cytotoxicity might be overcome by combing TRAIL-based therapy with drugs that reverse blockages of its apoptotic signaling. The gene discussed is TNFSF10; the disease is cancer.